Eisai and Biogen announced that Eisai has initiated a rolling submission to the US Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company’s investigational anti-amyloid beta (Aß) protofibril antibody, for the treatment of early Alzheimer’s disease (early AD).

Optimistic about the drug’s efficacy, the company has initiated its submission for accelerated FDA approval.

Resverlogix Corp., a world leader in epigenetics, or gene regulation, announces today new data that demonstrates their first-in-class oral small molecule BET inhibitor candidate Apabetalone significantly improves cognition and reduces cognitive decline among high-risk patients with cardiovascular disease and diabetes mellitus.

Approval of aducanumab will herald a new era in Alzheimer’s disease care and research.

The Food and Drug Administration’s controversial June 7 approval of aducanumab (Aduhelm) means that for the first time in 18 years, Alzheimer’s patients have a new treatment option.

NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced yesterday it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen’s lead compound, NVG-291, in validated animal models of Alzheimer’s disease.

NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen's lead compound, NVG-291, in validated animal models of Alzheimer's disease.

The Food and Drug Administration’s approval of Biogen and Eisai’s anti-amyloid antibody aducanumab on June 7 left many questions unanswered, including how to use the drug in clinical practice.